A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

NCT07293897 · clinicaltrials.gov ↗

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Alagille Syndrome (ALGS)
Progressive Familial Intrahepatic Cholestasis (PFIC)

Interventions

DRUG: Maralixibat

Sponsor

Takeda